<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665337</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-47676</org_study_id>
    <nct_id>NCT03665337</nct_id>
  </id_info>
  <brief_title>The Reducing Risk Study</brief_title>
  <official_title>Reducing Risk: A Comprehensive mHealth Sleep Health Intervention for Adolescents at Risk for Depression and Anxiety Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will test an innovative mobile health adaptation of a behavioral
      intervention that improves sleep and mental health concerns among adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>baseline to end of treatment (anticipated average exposure 2 months), months 3 and 8</time_frame>
    <description>Validated questionnaire; total score range between 0 and 21, with higher numbers representing worse sleep quality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the PHQ-9 (The 9 Item Patient Health Questionnaire For Depression)</measure>
    <time_frame>baseline to end of treatment (anticipated average exposure 2 months), months 3 and 8</time_frame>
    <description>A validated questionnaire measuring depressive symptom severity. The total score ranges between 0 and 19. Scores are rated as minimal (0-4), mild (5-9), moderate (10-14), and severe (15-19).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the SCARED (Screen for Child Anxiety Related Disorders) total score</measure>
    <time_frame>baseline, and at months 1, 2, 3 and 8</time_frame>
    <description>A validated 41-item questionnaire assessing self-report of anxiety in children and adolescents. Individual items are rated 'Not True or Hardly Ever True' (Score 0), 'Somewhat True or Sometimes True' (Score 1), or 'Very True or Often True' (Score 2). Individual response scores are then summed and for a total score. Total scores range from 0 to 82.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cortisol reactivity and recovery in response to a stress exposure</measure>
    <time_frame>baseline and at month 3</time_frame>
    <description>A validated biological measure of stress reactivity and recovery in response to a stress exposure. Changes in cortisol production at 15, 30 and 45 minutes following a stressor will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Insomnia</condition>
  <condition>Delayed Sleep Phase</condition>
  <arm_group>
    <arm_group_label>mTranS-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inJOY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>mTranS-C</intervention_name>
    <description>MOBILE HEALTH</description>
    <arm_group_label>mTranS-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>inJOY</intervention_name>
    <description>MOBILE HEALTH</description>
    <arm_group_label>inJOY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  any current psychiatric illness

          -  currently use of medications or herbs with known effects on sleep

          -  hospitalization for substance use or suicide within the past 12 months

          -  known sleep apnea

          -  unstable major medical conditions

          -  current psychotherapy for depression, anxiety or sleep health deficits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Asarnow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Asarnow, PhD</last_name>
    <phone>(415) 476-7439</phone>
    <email>Lauren.Asarnow@ucsf.edu</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

